Abstract 6074
Background
In Spain, we do not have real-time information about cancer survivors follow-up by their family doctor. The main objective of this study is to describe the characteristics and quality of life of cancer survivors followed at a primary care center in Northwest of Spain.
Methods
An individual interview was conducted with 100 survivors of breast or colon or lung cancer, all of them free of disease five or more years after their initial diagnosis. Socio-demographic variables, care plan and global quality of life assessment (using the EORTC QLQ-C30 questionnaire), were collected.
Results
We analyzed socio-demographic data of 72 women and 28 men. At the time of the interview, their median age was 66-years-old (37-99), most were married (61%), had primary studies (58%) and do not work (77 %). We analyzed aspects related to their global quality of life by using the EORTC QLQ-C30 questionnaire. A third (36%), acknowledged that their cancer diagnosis had influenced their employment status. More than 50% of survivors recognized asthenia and/or pain at the time of the interview, and at least a 15% and 20% of these cases respectively, related these symptoms to their previous diagnosis of cancer. More than a half (56%) acknowledged their previous cancer diagnosis had changed their lifes, and to a lesser extent the life of their family (28%) and economy. A 64% of the interviewed survivors considered that their enjoyed a good or a very good quality of life. Most ot the cancer survivors (75%) described themselves as cured people.
Conclusions
Most survivors recognized that their cancer diagnosis changed their lives, and up to a third of the cases also their work situation. However, the majority of survivors report a globally good quality of life and describe themselves as cured people.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Begoña Graña.
Funding
SEOM - "Oncovida" scholarship.
Disclosure
B. Grana Suarez: Research grant / Funding (institution), Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: Celgene; Research grant / Funding (institution): Roche; Travel / Accommodation / Expenses: Servier. All other authors have declared no conflicts of interest.
Resources from the same session
4822 - Efficiacy of different nutritional intervention on nutritional status and quality of life for local advanced nasopharyngeal carcinoma patients: a prospective clinical trial
Presenter: Yuan-yuan Chen
Session: Poster Display session 3
Resources:
Abstract
2628 - Apatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma
Presenter: Changjuan Tao
Session: Poster Display session 3
Resources:
Abstract
4887 - Impact of tumor site and adjuvant radiotherapy on survival of adenoid cystic carcinoma: a SEER database analysis
Presenter: Jason Tasoulas
Session: Poster Display session 3
Resources:
Abstract
2634 - Efficacy and safety of anlotinib for patients with recurrent and/or metastatic salivary gland carcinomas
Presenter: Wen Jiang
Session: Poster Display session 3
Resources:
Abstract
3568 - ACCURACY a phase (P) 2 trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): preliminary safety and efficacy data.
Presenter: Renata Ferrarotto
Session: Poster Display session 3
Resources:
Abstract
683 - Pathologic Staging Changes in Oral Cavity Squamous Cell Carcinoma—Stage Migration and Implications for Adjuvant Treatment
Presenter: Zain Husain
Session: Poster Display session 3
Resources:
Abstract
563 - Expression of immune response biomarkers in head and neck squamous cell carcinoma (HNSCC) in irradiated area
Presenter: Carole Pflumio
Session: Poster Display session 3
Resources:
Abstract
4030 - HLA-Ligandome analysis reveals target antigens of oropharyngeal squamous cell carcinoma
Presenter: Simon Laban
Session: Poster Display session 3
Resources:
Abstract
2979 - Topographical distribution of sentinel lymph nodes in early tongue squamous cell carcinomas
Presenter: Hiroyuki Goda
Session: Poster Display session 3
Resources:
Abstract
3517 - Role of follow-up (FU) FDG-PET/CT (FU-FDG-PET/CT) in patients with locoregionally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) treated with chemotherapy and radiotherapy (RT), either concurrent (CRT) or sequential (ST).
Presenter: Bert Van Den Heuvel
Session: Poster Display session 3
Resources:
Abstract